towards a higher rate of complete occlusion with the FRED device.

	FRED	Pipeline	p-value
Age*	59.1 ± 10.7	49.1 ± 13.8	0.02
Male	4 (21%)	10 (27.8%)	0.7
Previously ruptured	1 (5%)	4 (11%)	0.65
Retreatment(Previously coiled)	4 (21%)	8 (22%)	1
Coils Placed at the time of treatment	1 (5%)	2 (5%)	1
Multiple Devices	3 (16%)	5 (14%)	1
Fusiform	2 (11%)	9 (25%)	0.3
PRU at time of procedure	122 ± 63	124 ± 67	0.9

There was no significant difference between the complication rates for the two groups, including ipsilateral ischemic stroke, ipsilateral ICH, aneurysm rupture and overall neurological morbidity and mortality.

FRED	ICA > 10 mm	ICA < 10 mm	All
	(n = 10)	(n = 7)	(n = 19)
Ipsilateral Ischemic Stroke	1 (10%)	1 (14%)	2 (10.5%)
Ipsilateral ICH	0 (0%)	0 (0%)	0 (0%)
Aneurysm Rupture	0 (0%)	0 (0%)	0 (0%)
Neurological Morbidity &	1 (10%)	1 (14%)	2 (10.5%)
Mortality			
Pipeline	ICA > 10 mm	ICA < 10 mm	All
	(n = 3)	(n = 26)	(n = 36)
Ipsilateral Ischemic Stroke	0 (0%)	2 (7.7%)	3 (8.3%)
Ipsilateral ICH	0 (0%)	1 (3.8%)	1 (2.7%)
Aneurysm Rupture	0 (0%)	0 (0%)	0 (0%)
Neurological Morbidity &	0 (0%)	3 (11.5%)	4 (11.1%)

There was no significant difference in occlusion rate between the two groups. There was a trend towards a higher rate of complete occlusion in the FRED group but this was not statistically significant (p=0.17). When only saccular aneurysms were evaluated, the complete occlusion rate in the FRED group was 92.3% and 70% in the pipeline group (p=0.2).

FRED	Anterior	All
6 month angiographic complete occlusion	11/13 (84.6%)	11/14 (78.6%
12 month angiographic complete occlusion	7/8 (87.5%)	7/8 (87.5%)
Any follow up imaging	13/14 (92.9%)	13/15 (86.7%
Pipeline	Anterior	All
6 month angiographic complete occlusion	7/9 (77.8%)	7/10 (70%)
12 month angiographic complete occlusion	NA	NA
Any follow up imaging	14/21 (66.7%)	17/26 (65.4%

Disclosures A. Paul: None. J. Dalfino: None. J. Yamamoto: None. A. Boulos: None.

0-019

NOVEL METHOD FOR INTRACRANIAL DEPLOYMENT OF 6 AND 8 MM DIAMETER SELF EXPANDING COBALT CHROMIUM STENTS IN THE ARTERIAL AND VENOUS CIRCULATIONS

C Martin, I Akhtar, J Halpin, W Holloway, N Akhtar. Marion Bloch Neuroscience Institute, Saint Luke's Hospital of Kansas City, Kansas City, MO

10.1136/neurintsurg-2016-012589.19

Introduction/purpose Stents for the intracranial circulation are approved for stent assisted coiling of brain aneurysms, flow diversion of brain aneurysms and atherosclerotic occlusive disease. These stents are deliverable and approved for intracranial placement of cerebral arteries ranging in size from 2.5 to 4.5 mm. The relatively small stents are unsuitable for skull based internal carotid artery for dissection and venous sinus deployment due to the large diameter of these vessels. Self-expandable cobalt chromium carotid stents are properly sized to these circulations but do not track the curvatures of the intracranial arterial and venous circulations. These self-expanding cobalt chromium carotid stents are available in 6 and 8 mm diameter sizes and, due to the braided design, these implants will track curves when partially deployed. We report a technique of partially deploying a cobalt chromium stent within a 072 intracranial support catheter which has already been positioned distal to the target. This allows the stent to be advanced around curves and unsheathed directly from the catheter thus allowing intracranial stenting of larger vessels.

Materials and methods This is a retrospective review of 11 cases in which cobalt chromium stents were placed in the intracranial circulation at our facility over a two year period. These stents were placed with an 072 intracranial support catheter positioned distal to the target. Three stents were placed in distal cervical ICA transitioning into the horizontal petrous ICA. Eight stents were placed in the venous circulation (1 straight sinus to transverse sinus, 5 transverse sinus, 1 transverse-sigmoid junction, 1 sigmoid-jugular junction). In two venous cases, the stents were used to support coil masses. Results All cases in which the cobalt chromium stents were deployed were successful. No neurological sequelae were observed post procedure.

Conclusion This technique allows for a wider range of stent sizes to access the tortuous intracranial circulation and provides an additional tool to the neurointerventional surgeon.

Disclosures C. Martin: None. I. Akhtar: None. J. Halpin: None. W. Holloway: None. N. Akhtar: None.

0-020

WEB® ANEURYSM TREATMENT: PRELIMINARY RESULTS OF WEBCAST 2 STUDY

L Pierot, A Molyneux, J Byrne. Radiology, Hôpital Maison-Blanche, Reims, France

10.1136/neurintsurg-2016-012589.20

Purpose WEB Flow disruption is an innovative endovascular treatment for wide-neck bifurcation aneurysms. This treatment was already evaluated in several retrospective and prospective series, including 2 Good Clinical Practice (GCP) studies (WEB-CAST and French Observatory) showing high safety and good efficacy. In WEBCAST, all patients were treated with the first generation of the device (WEB-DL) and WEBCAST2 was initiated to evaluate the second generation of the device (WEB-SL and WEB-SLS).

JNIS 2016;**8**(1):A1—A100

Methods Patients with wide neck bifurcation aneurysm were included in WEBCAST2 if the aneurysm was not previously treated. An independent medical monitor independently analyzed adverse events. Follow-up imaging was obtained at 6 and 12 months up to 5 years after the procedure. An independent expert in Interventional Neuroradiology evaluated anatomical results using the 3 grades scale: complete occlusion, neck remnant, and aneurysm remnant.

Results From August 14 to May 15, 55 patients (38 females, 69.0%) with 55 aneurysms including 4 ruptured (7.2%) were included. Aneurysm locations were: middle cerebral artery in 25 patients (46.0%), anterior communicating artery in 16 patients (29.0%), basilar artery in 9 patients (16.0%), and internal carotid artery terminus in 5 patients (9.0%). Placement of the WEB device was feasible in 53/55 aneurysms (96.4%). Forty-seven aneurysms were treated with the WEB-SL and 6 with WEB-SLS. Adjunctive devices were used in 4 patients (7.3%). Procedure-related morbidity and mortality at one month were reported in 1/54 patients (1.8%) and 0/54 patients (0.0%), respectively (1 patient was missing one-month follow-up).

Anatomical results at 6 months were complete aneurysm occlusion in 28/49 aneurysms (57.1%), neck remnant in 11/49 aneurysms (22.4%), and aneurysm remnant in 10/49 aneurysms (20.4%).

Conclusion Preliminary results of WEBCAST2 show similar safety and efficacy of WEB-SL/SLS compared to WEB-DL (WEBCAST) with low morbidity and no mortality and a high rate of adequate occlusion (79.5%).

Disclosures L. Pierot: 2; C; Sequent. A. Molyneux: 2; C; Sequent. J. Byrne: 2; C; Sequent.

0-021

FLOW DIVERSION IN RUPTURED INTRACRANIAL ANEURYSMS: A SYSTEMATIC REVIEW

T Madaelil, C Moran, D Cross, A Kansagra. *Neuroradiology, Mallinckrodt Institute of Radiology, Saint Louis, MO*

10.1136/neurintsurg-2016-012589.21

Background and purpose Flow diversion is an established technique to treat unruptured intracranial aneurysms not amenable to standard endovascular or microsurgical techniques. The suitability of flow diverting devices (FDD) to treat ruptured aneurysms is less clear.

Materials and methods An in-depth search of multiple electronic publication databases was performed for reports describing ruptured intracranial aneurysms treated by flow diversion. Clinical and radiological characteristics, interventional details, and outcomes were pooled and analyzed in aggregate.

Results The pooled cohort comprised of 126 patients with a mean age of 52.6 ± 12.5 years. Mean Hunt Hess/World Federation of Neurosurgical Societies grading scale at presentation was 2.2 ± 1.2 . Treated aneurysms were located in the anterior circulation in 64% (81/126) cases and 36% (45/126) in the posterior circulation. Five distinct aneurysm morphologies were present, including dissecting (28%, 35/125), fusiform (9.6%, 12/125), giant (3.2%, 4/125), blister (37.6%, 47/125), and saccular (21.6%, 27/125) types. Favorable clinical outcome (defined as Modified Rankin Scale (mRS) = 0-2 or Glasgow Outcome Scale (GOS) = 4-5) was achieved in 81.5% (101/124) of treated patients. Unfavorable clinic outcome (defined by mRS = 3-6 or GOS = 1-3) occurred in 18.5% (23/124)

of patients. Clinically significant hemorrhagic complications occurred in 5.5% (7/126) of cases, the majority of which were due to aneurysm re-rupture (4.8%; 6/126). Aneurysm size greater than 2 cm was associated with a greater risk of re-rupture when compared to aneurysms smaller than 2 cm (p = 0.001). Aneurysm size greater than 7 mm was associated with more unfavorable clinical outcomes (p = 0.03).

Conclusion For ruptured aneurysms not amenable to other treatment strategies, the use of flow diversion may allow for reasonably high rates of good clinical outcomes, particularly in small aneurysms. There was a risk of re-rupture in these aneurysms, especially those larger than 2 cm.

Disclosures T. Madaelil: None. C. Moran: 2; C; Medtronic Neurovascular. D. Cross: None. A. Kansagra: None.

0-022

GENERAL ANESTHESIA, BASELINE ASPECTS, TIME TO TREATMENT, AND IV TPA IMPACT INTRACRANIAL HEMORRHAGE AFTER STENTRIEVER THROMBECTOMY: POOLED ANALYSIS FROM SWIFT PRIME, SWIFT AND STAR TRIALS

¹R Raychev, ²J Saver, ³R Jahan, ⁴R Nogueira, ⁵M Goyal, ⁶V Pereira, ⁷J Gralla, ⁸E Levy, ⁹D Yavagal, ¹⁰C Cognard, ¹¹D Liebeskind. ¹Saddleback Memorial Medical Center, Laguna Hills, CA; ²Neurology, UCLA Stroke Center, Los Angeles, CA; ³Division of Interventional Neuroradiology, UCLA, Los Angeles, CA; ⁴Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Department of Neurology, Emory University School of Medicine, Atalanta, GA; ⁵Departments of Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; ⁶Toronto Western Hospital/University of Toronto, Toronto, ON, Canada; ⁷Inselspital, University of Bern, Bern, Switzerland; ⁸Department of Neurosurgery, SUNY at Buffalo, Amherst, NY; ⁹University of Miami/Jackson Memorial Hospital, Miami, FL; ¹⁰Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Toulouse, Toulouse, France; ¹¹Neurovascular Imaging Research Core, Department of Neurology, UCLA, Los Angeles, California, USA, Los Angeles, CA

10.1136/neurintsurg-2016-012589.22

Introduction Despite the proven benefit of Solitaire for treatment of acute ischemic stroke, symptomatic intracranial hemorrhage (ICH) remains the most feared procedural complication. The aim of this analysis was to identify the factors determining ICH after neurothrombectomy with Solitaire stentriever.

Methods All patients (N = 389) treated with Solitaire in SWIFT, SWIFT PRIME, and STAR trials were analyzed for incidence of 5 different ICH subtypes. Each ICH subtype was correlated with baseline clinical, imaging and procedural characteristic (age, NIHSS, hypertension, diabetes, atrial fibrillation, hyperglycemia, INR, platelet count, ASPECTS, general anesthesia, collateral grade, number of devices passes, final TICI, rescue therapy, IV TPA). Multivariate stepwise logistic regression model was used to identify the predictors of individual ICH subtypes.

Results ICH was observed in 21.6% (N = 84) of which sICH was 1.0% (N = 4), hemorrhage in ischemic territory (HIT) 19.3% (N = 75), PH 5.4% (N = 21), and SAH 2.3% (N = 9). The most significant predictors of any ICH, HIT, and PH are included in Table 1. No specific predictors of SAH, and sICH were identified. Patients who achieved functional independence at 90 days (mRS 0–2) had significantly lower incidence of any ICH, HIT, PH, and no SICH (Table 2).

Conclusions Higher baseline ASPECTS, better collaterals and general anesthesia are associated with lower incidence of ICH after neurothrombectomy with Solitaire stentriever. Prolonged

A14 J/N/S 2016;**8**(1):A1-A100